Articles On Proteomics International Laboratories (ASX:PIQ)

Proteomics International Laboratories will continue important research and development for its diagnostic test products after meeting key guidelines set by the International Organisation for Standardisation.

Proteomics International Laboratories’ 66 per cent-owned subsidiary OxiDx has been awarded a European patent for its finger-prick technology used in monitoring and measuring levels of oxidative stress.

Proteomics International Laboratories (ASX:PIQ) subsidiary, OxiDx, has secured a patent across 19 major European countries for its platform technology designed to assess oxidative stress Oxidative stress has diverse applications, ranging...

  Neuren’s Daybue sales meet target Proteomics granted patent in Europe Nyrada’s brain injury drug shows efficacy in animal testing   Neuren’s Daybue sales meet target, crushing short seller’s claims Neuren Pharma (ASX:NEU) says Q4 2023 s...

  Expert says buy US bonds now to lock in yields Viking Therapeutics doubled and Janux Therapeutics tripled after updates Microsoft makes another huge AI bet   The ASX is poised to open slightly higher on Wednesday after a mixed session...

The United States’ biggest government-funded healthcare provider Medicare has locked in a payment rate of US$390.75 for Proteomics International Laboratories’ PromarkerD test for diabetic kidney disease.

Alterity Therapeutics gets firm commitments for $4.8 million in capital raise Mesoblast partners with the Blood and Marrow Transplant Clinical Trials Network for pivotal trial Centers for Medicare & Medicaid Services (CMS) in US confir...

Proteomics International Laboratories’ share price has hit a seven-month high after a United States federal health agency set a national reimbursement price for the company’s “PromarkerD” diabetes test.

PIQ came out of trading suspension and surged 13pc PIQ says the US has set a national reimbursement price for PromarkerD Kazia awarded a late breaking oral presentation for paxalisib   Proteomics International Laboratories (ASX:PIQ) surge...

Stockhead’s Top 10 at shortly-before-11-ish, produced in a tearing rush because it’s the Friday before a long weekend in the middle of the school holidays so of course everyone’s got ‘the flu’, or their grandma has died for the third time t...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

ASX 200 ends sharply lower on Monday, down 0.67% All Sectors  close in the red, with InfoTech taking the worst of the damage Small caps led by lithium minnows RR1, WC8 and VCM Australian shares have joined most Asian markets in a retre...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P...

Proteomics International (PIQ) is preparing to present its latest results from the company’s novel blood test for oesophageal adenocarcinoma The company will showcase results from its PromarkerEso blood test at the 19th ISDE World Congre...

Proteomics International Laboratories has revealed new results showing that refinement of its simple “PromarkerEso” blood test correctly identified 89 per cent of patients with a type of oesophageal cancer.

Futures indicate the ASX is poised to open lower this morning as Wall Street grapples with the repercussions of China’s potential ban on Apple iPhones. Meanwhile, Australia’s regulator, ASIC, has filed a lawsuit against the country’s lar...

ASX to open flat after a mixed session on Wall Street Semiconductor stocks slumped in US and Europe after China’s iPhone ban This expert says small caps are undervalued   Australian shares are set for a muted open on Friday after a mixed...

Proteomics International Laboratories has been granted a breakthrough patent in Japan for its finger prick technology that determines oxidative stress protein biomarkers implicated in chronic diseases.

Genetic Signatures jumps on FDA 510(k) application Allegra says FDA has questions related to its 510(k) application Proteomics granted patent in Japan   Genetic Signatures jumps almost 20pc on FDA update There were a couple of FDA-related...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ALG)) - Ardent Leisure ((ABB)) - Aussie Broadband ((AFG)) - Australian Finance Group ((AVG)) - Australian Vintage ((BVS)) - Bravura Solutions ((CBO)) - Cobram Estate Oli...

Proteomics International Laboratories has seen its cash receipts from clients increase by 5.8 per cent to $198,000 in the June quarter, as the company eyes its first sales in the United States in December.

Trailblazing medtech Proteomics International Laboratories has been chosen to put its oesophageal cancer blood test on global show at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada.

EBR announces positive results of its pivotal SOLVE-CRT trial at Heart Rhythm 2023 in US EBR latest ASX biotech company to achieve a key catalyst, opening door to US$2.5 billion market Company now working on regulatory and commercialisatio...

ASX health stocks rise in the past five days outperforming broader markets Avita Medical product sales up 40% on pcp to US$10.5 million in Q1 FY23 Proteomics International Laboratories inks a deal with Sonic Healthcare USA Healthcare and...

Proteomics International Laboratories has secured a key partner for the looming roll-out of its PromarkerD predictive test to fight kidney disease by signing an exclusive licence deal with Sonic Healthcare USA.

Proteomics International (PIQ) signs an exclusive licence agreement with Sonic Healthcare USA to commercialise PromarkerD in the US PromarkerD is a newly developed blood test able to predict a decline in kidney function in type two diabe...

The ASX 200 benchmark has posted a solid slab of gains, up 0.78% for the day Energy and Materials have teamed up to bring the winnings, at +2.5% and +1.6% respectively Creso Pharma’s buy-out of HHI delivers strong backing from investors, u...

ASX health stocks fall 0.8% in the past five days in line with broader markets following latest rate hike Investors rewarding health stocks with near term catalysts in 2023, including Neuren and Impedimed Health imaging stock Volpara recor...

Proteomics International Laboratories has strengthened its fight against kidney disease with the identification of a diabetes drug that has boosted the prospects of its PromarkerD predictive test.

Diabetes drug Canagliflozin lowers Proteomics’ PromarkerD diabetic prediction scores Artrya says Q-Submission (Q-Sub) has now been lodged with the FDA Universal Bio launched the PETRACKR blood glucose monitoring product for pets   Protemi...

The ASX will open lower this morning after a 1% fall on Wall Street US regional bank stocks tumbled again Oil prices crashed around 5% on recession fears   The ASX is poised to tumble on Wednesday, tracking the moves in New York. At 8am A...

ASX-listed Proteomics International Laboratories has beefed up its clinical advisory board ahead of the rollout of its Promarker D predictive test for diabetic kidney disease in type 2 diabetes patients.

Proteomics International Laboratories’ plans for the global launch of its PromarkerD test for predicting diabetic kidney disease have received a significant boost with the renewal of two key accreditations.

Proteomics is confident of finalising a deal with Sonic Healthcare to use its PromarkerD test in its US labs Promising results of new blood test show it could transform how endometriosis is diagnosed in women Morgans said a deal with Sonic...

ASX health stocks rise 0.97% in the past five days in line with broader markets Impedimed up 99% after BIS tech named in latest US NCCN guidelines for lymphoedema  EBR Systems to release top line results at cardiac conference Heart Rhythm...

Benchmark set to finish close to flat as Energy stocks slump again Goldies are surging again, with that sector up 1.3% for the day Even the big banks are bracing for trouble with talk of a crisis getting louder by the day   After a modera...

Proteomics International Laboratories says it has developed a simple new blood test to identify up to 90 per cent of patients with endometriosis, following a study of more than 900 participants.

ASX health stocks fall 1.5% in the past five days, broader markets fall on global banking concerns Neuren Pharmaceuticals has soared 60% after FDA approves its drug for Rett’s syndrome  Antisense starts chronic monkey toxicology study of A...

Proteomics International Laboratories (ASX:PIQ) has announced that it will resubmit its application to have the PromarkerD predictive test for diabetic kidney disease funded via Medicare.

ASX health stocks fall 1.87% in the past five days as reporting season ends Healius moves to a statutory loss of ~$29 million following reduced demand for Covid-19 testing Catalysts in next few months for several ASX health stocks which co...

Tony Locantro, Alto Capital BUY RECOMMENDATIONS Proteomics International Laboratories (PIQ) The company’s PromarkerD test can predict future kidney function decline in patients with type 2 diabetes, and with no existing diabetic kidney dise...

Proteomics International Laboratories (PIQ) extends its exclusive distribution agreement for PromarkerD in Great Britain The company added an additional five years to its existing deal with medical diagnostics company Apacor to bring its...

ASX health stocks rise 4.6% this week with positive signs of being back in favour Volpara soars after announcing its first net cash flow positive quarter Morgans basket of healthcare stock picks for 2023 faring well,  all up YTD Healthca...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX health stocks rise 0.8% this week as smaller names in sector show signs of being back in favour Volpara signs five 5-year contracts worth more than US$7.8 million in Total Contract Value Mach 7 continues its 2023 recovery after announc...

The ASX Health sector has fallen ~1.5% in its first trading week of 2023 Mach7  has surged after landing its largest ever customer contract Proteomics gets US approval for PromarkerD test for diabetic kidney disease Healthcare and life sc...

An exclusivity deal for use of Proteomics International Laboratories’ early diabetic kidney disease detection test by Sonic Healthcare USA is close, with the two firms extending a letter of intent.

Aussie shares set to extend gains on Thursday Wall Street pared gains after Fed minutes release China to partially lift ban on Aussie coal   Aussie shares are set to open higher on Thursday, tracking the rally in New York. At 8am AEDT, th...